Kite adds promising leukemia responses in small CAR-T studies, then fires the starting gun on its rolling submission
Kite Pharmaceuticals $KITE has lined up a fresh batch of positive efficacy data for its lead CAR-T for advanced cases of acute lymphoblastic leukemia at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
